Sartor, A. O., Tagawa, S. T., Lenzo, N., Cade, D., Agarwal, N. (2025). ProstACT GLOBAL: A phase 3 study of 177 Lu-rosopatamab (TLX591) with and without the best standard of care for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps303